GLP-1 Pregnancy Safety: Semaglutide and Tirzepatide
You are pregnant or planning to become pregnant. You are on a GLP-1 medication, or you are thinking about starting one and wondering whether pregnancy is possible while on the medication. The question is urgent and understandably confusing. The simple answer: GLP-1 medications are not recommended during pregnancy. If you are planning to conceive, you will need a plan for when to stop the medication.
This page covers what the FDA labels say, what is and is not known from human data, what happens if you become pregnant while taking GLP-1, and practical guidance for women of childbearing age who are considering these medications.
What the FDA Label Says
The FDA labels for the brand-name products Wegovy (semaglutide) and Zepbound (tirzepatide) both address pregnancy.[1][2] Both say that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and both say to discontinue the medication for weight loss when a pregnancy is recognized. (The Wegovy label adds that, when it is used to treat MASH with advanced liver fibrosis, it should be used in pregnancy only if the potential benefit justifies the potential risk.)[1]
The labels differ on planning ahead. The Wegovy label says to discontinue at least 2 months before a planned pregnancy to account for the long half-life of semaglutide.[1] Semaglutide has a half-life of about 1 week, and the label says it stays in the circulation for about 5 to 7 weeks after the last dose.[1] The Zepbound label says to discontinue when a pregnancy is recognized and does not list a specific washout period before a planned pregnancy.[2]
These are label instructions for prescribers, not optional extras. A provider prescribing a GLP-1 medication should discuss them with you if you could become pregnant.
Why Are These Medications Not Recommended in Pregnancy?
Three things inform the FDA’s warning: animal reproduction data, the newness of these medications in human use, and the theoretical risk of off-target effects during a critical window of fetal development.
Animal Reproduction Studies
In animal studies described on the labels, semaglutide was linked to embryo-fetal death, structural abnormalities, and growth changes, and tirzepatide to fetal growth reductions and fetal abnormalities.[1][2] These effects occurred at clinically relevant exposures, meaning drug levels in the animals’ blood were in the range seen with human doses. On both labels, the fetal effects coincided with reduced maternal body weight and food intake.[1][2]
This is important context: Animal reproduction data does not always predict what will happen in humans. But it is the main evidence available, and it is the basis for the pregnancy warning on both labels.
Limited Human Data
GLP-1 medications, particularly semaglutide and tirzepatide, are relatively new. Semaglutide was first approved in the US in 2017 and tirzepatide in 2022.[1][2] These medications have not been studied in large, prospective randomized trials of pregnant women, nor would they be for ethical reasons. Both labels say the available human data are insufficient to establish a drug-related risk of major birth defects, miscarriage, or other adverse outcomes.[1][2]
What exists are case reports and pharmacovigilance data collected as providers and patients report outcomes. The Wegovy label lists a pregnancy exposure registry run by Novo Nordisk, and the Zepbound label says Eli Lilly and Company will run one.[1][2] The evidence base remains limited compared to other medication classes with decades of pregnancy registry data.
Critical Window of Development
Major organ systems form during the very early weeks of pregnancy, often before a pregnancy is recognized. If you conceive soon after stopping semaglutide, the medication may still be present in your bloodstream during this period, since the Wegovy label says it stays in the circulation for about 5 to 7 weeks after the last dose.[1] The Wegovy label’s 2-month instruction accounts for that.
What Happens if You Become Pregnant While on GLP-1?
This is a real scenario because unplanned pregnancy is common, and women on GLP-1 may not immediately realize they are pregnant if they have irregular cycles (which can improve with GLP-1 treatment).
If you find out you are pregnant while taking a GLP-1 medication:
Contact your prescribing provider immediately. Do not wait for a scheduled appointment. Call and explain that you have just discovered you are pregnant and are currently on a GLP-1 medication. Your provider needs to know this right away.
Tell your OB/GYN as well. Your OB/GYN should be aware that you were taking a GLP-1 medication before you became aware of the pregnancy.
The labels say to discontinue the medication for weight loss when a pregnancy is recognized.[1][2] Your provider can then review your specific situation, including:
- How long you were on the medication before you found out you were pregnant
- At what stage of pregnancy you are now
- Whether you had any unplanned dose timing (for example, did you take your weekly injection after conception occurred)
- Your individual medical history
Early discovery of pregnancy while on GLP-1 is a different scenario than ongoing intentional use throughout pregnancy. Your provider can evaluate the specifics of your situation and discuss what monitoring, if any, may be appropriate.
The key is: Do not continue taking GLP-1 medication during pregnancy without explicit direction from your prescriber. If you discover you are pregnant, your first step is to contact your provider.
A Critical Point for Women with PCOS
If you have PCOS (polycystic ovary syndrome), this next part is especially important for you.
One of the reasons many women start GLP-1 medications is metabolic benefit. In small trials in women with PCOS, GLP-1 medications improved insulin sensitivity and lowered BMI more than metformin, though the authors rated the evidence moderate to low quality.[3] Insulin resistance is a core problem in PCOS. As insulin resistance improves and weight comes down, ovulation may return in some women. That can be good news for fertility, and some women with PCOS who had irregular cycles or believed they had low fertility see their cycles become more regular. Results vary.
But here is the practical consequence: A woman who started GLP-1 thinking “I have PCOS and cannot easily get pregnant” may become pregnant unexpectedly while on the medication, before she intended to stop it.
If you have PCOS and are considering GLP-1 treatment, you need to think about contraception separately from the medication decision. Effective, reliable contraception is essential if you are not actively trying to conceive. Even if you have a history of irregular cycles or fertility challenges, GLP-1 treatment can shift your fertility status. Your provider can discuss which contraceptive option works best for you while you are on GLP-1.
GLP-1 and Oral Contraceptive Absorption
If you are using oral birth control pills for contraception, there is another layer to this conversation: GLP-1 medications slow gastric emptying,[1][2] meaning food (and medication) moves more slowly through your stomach. This delayed emptying can affect how well your body absorbs oral medications.
The Zepbound label warns that tirzepatide may make oral hormonal contraceptives less effective. The effect is largest after the first dose and lessens over time.[2] The Wegovy label does not include this instruction.[1] You should discuss your birth control with your provider, particularly:
- If you are just starting a GLP-1 medication and are relying on oral contraception
- If you increase your dose of GLP-1 medication
For tirzepatide, the label says to switch to a non-oral contraceptive method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.[2] The Zepbound label also says hormonal contraceptives that are not taken by mouth, such as a hormonal IUD or implant, should not be affected.[2] If you take the pill and are starting or increasing any GLP-1 medication, confirm your backup plan with your prescriber.
The point is: Do not assume your birth control pills are equally effective while on GLP-1. Have that conversation with your provider.
Pregnancy Planning: A Timeline
If you are thinking about becoming pregnant in the next 6 to 12 months, here is a realistic timeline to discuss with your provider:
Months 1-2: You and your provider discuss your pregnancy timeline and your GLP-1 treatment. If you are considering GLP-1 and want to become pregnant soon, the medication may not be the right choice. If you are already on GLP-1, agree on a stop date based on your medication’s label: at least 2 months before you start trying for Wegovy (semaglutide).[1]
Months 3-4: If you stopped semaglutide to prepare for conception, the medication is clearing your system during this window. Your provider may discuss nutrition and exercise planning during this time to maintain healthy habits while you are not on medication.
Months 5+: You can begin trying to conceive once the waiting period your prescriber recommends has passed. You and your provider can focus on other aspects of reproductive health, such as prenatal vitamins (including folic acid, which is important for neural tube development in early pregnancy).
The exact timeline depends on your medication, your provider’s assessment, and your specific health situation. For semaglutide, the key is: Do not stop and immediately try to conceive. Build in the 2-month period first.[1] For tirzepatide, the Zepbound label does not list a washout period, so ask your prescriber how far ahead to stop.[2]
What Happens After Delivery
This question comes up often: “Can I get back on GLP-1 after my baby is born?”
For many women it is possible, but with important considerations.
If you are breastfeeding: The labels differ by product.[1][2] The Wegovy label says breastfeeding is not recommended during treatment with Wegovy tablets, because an absorption enhancer in the tablets (SNAC) passes into breast milk. For Wegovy injection, there are no data on semaglutide in human milk, effects on the breastfed infant, or milk production. For Zepbound, a single-dose study found tirzepatide in breast milk was undetectable or low, and there are no data on effects on the breastfed infant or milk production. For the injections, both labels say to weigh the benefits of breastfeeding against your clinical need for the medication and any potential effects on the baby. Make this decision with your prescriber and your baby’s pediatric provider.
If you are not breastfeeding: You can discuss restarting GLP-1 with your provider after delivery. Your provider will consider factors such as:
- Your physical recovery from pregnancy and delivery
- Your current health status and any postpartum complications
- Whether you are getting adequate nutrition if you are still recovering
- Your postpartum mood and mental health
Pregnancy and the postpartum period involve significant hormonal and physical changes. Your provider may recommend waiting a few weeks or months before restarting medication, to let your body stabilize and to allow adequate time for nutrition and recovery.
The conversation should happen during your postpartum visit. Plan to bring this up with your OB/GYN so that your OB/GYN and your prescriber can coordinate.
Medication Management and Informed Decision-Making
GLP-1 medications are clinical tools used for metabolic health and weight management. But they require informed decision-making, particularly if you are a woman who might become pregnant.
Here is what you need to know before starting a GLP-1 medication:
- GLP-1 medications are not used for weight loss during pregnancy; Wegovy (semaglutide) should be stopped at least 2 months before a planned pregnancy, and Zepbound (tirzepatide) when a pregnancy is recognized
- If you are planning to become pregnant in the next 3-6 months, GLP-1 may not be right for you at this time
- If you are not planning pregnancy but are having unprotected sex or using unreliable contraception, discuss effective contraception with your provider before starting GLP-1
- If you are on oral contraceptive pills, discuss how GLP-1 affects pill effectiveness (the Zepbound label calls for a non-oral or backup method for 4 weeks after starting and after each dose increase)
- If you become pregnant while on GLP-1, contact your provider and OB/GYN immediately
- If you have PCOS, understand that improved fertility may come sooner than you expect, and plan contraception accordingly
A licensed provider should discuss all of these points with you before prescribing. If your provider does not bring these up, you should.
Practical Next Steps
If you are pregnant or planning pregnancy and you are currently on or considering a GLP-1 medication, here is what to do:
Schedule a conversation with your prescribing provider about your pregnancy plans or current pregnancy. Be direct about the timeline.
If you are pregnant right now: Contact your provider today, inform your OB/GYN, and get guidance on stopping your medication safely.
If you are planning pregnancy in the next 3-6 months: Discuss whether GLP-1 is the right choice for you at this time, or whether stopping the medication and timing your conception is a better plan.
If you are not planning pregnancy but could become pregnant: Discuss contraception options that work well with GLP-1 treatment. On tirzepatide, do not rely on oral contraceptive pills alone during the first 4 weeks and for 4 weeks after each dose increase.
Get a full medical evaluation: A licensed provider should review your complete health history and discuss whether GLP-1 is appropriate for you, given your current situation and reproductive plans.
Citations
[1] Novo Nordisk. Wegovy (semaglutide) prescribing information. US Food and Drug Administration. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Section 8.1: pregnancy, animal data, insufficient human data, pregnancy exposure registry; section 8.2: lactation; section 8.3: stop at least 2 months before a planned pregnancy; section 12.3: half-life about 1 week, present in circulation about 5 to 7 weeks after the last dose.)
[2] Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Section 8.1: stop when pregnancy is recognized, animal data, insufficient human data, planned registry; section 8.2: lactation; section 8.3: oral hormonal contraceptive instructions.)
[3] Han Y, Li Y, He B. “GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.” Reproductive BioMedicine Online. 2019;39(2):332-342. https://pubmed.ncbi.nlm.nih.gov/31229399/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, and never start, stop, or change a medication without guidance from your prescriber, including during pregnancy planning. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review them for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency. Label information on this page applies to the brand-name products studied. Results vary. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.